1191908-84-5

Basic information

• Product Name: 1-(1-isonicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea
• Synonyms: 1-(1-isonicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea
• CAS NO: 1191908-84-5
• Molecular Weight: 408.38
• Mol File: 1191908-84-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1-(1-isonicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1-isonicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea(1191908-84-5)
• EPA Substance Registry System: 1-(1-isonicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea(1191908-84-5)

Safety Data

• Hazardous Substances Data: 1191908-84-5(Hazardous Substances Data)

Usage

General Description

The chemical compound "1-(1-isonicotinoylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea" is a urea derivative that contains a piperidine ring and a trifluoromethoxyphenyl group. It is also known by the name "Compound 24" and has been studied for its potential therapeutic applications, particularly in the treatment of cancer. The compound has shown promising activity as a kinase inhibitor, particularly targeting protein kinase C (PKC) and Aurora kinase. Its unique structure and properties make it a potential candidate for the development of novel anticancer drugs. Further research and development of this compound may lead to the discovery of new treatments for cancer and other diseases.

Upstream product

• 55-22-1 pyridine-4-carboxylic acid 

Relevant articles and documents

1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: Structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain

1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure-activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl) piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in Cmax, and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl) urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.